← Search & browse all drugs

denileukin diftitox

L01XX29

Forms & Strengths

Intravenous solution: 150 mcg/mL in 2 mL single-dose vials

Adult Dosing

Cutaneous T-cell lymphoma: 9 or 18 mcg/kg/day administered as an intravenous infusion over at least 15 minutes for 5 consecutive days per 21-day cycle

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established

Indications

Treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose cells express the CD25 component of the IL-2 receptor

Mechanism of Action

A recombinant fusion protein combining the sequences for diphtheria toxin and interleukin-2 (IL-2), targeting cells expressing the IL-2 receptor (CD25) and inhibiting cellular protein synthesis via cell-surface binding, internalization, and ADP-ribosylation of elongation factor 2

Contraindications

Known hypersensitivity to denileukin diftitox, diphtheria toxin, interleukin-2, or any component of the formulation

Adverse Reactions

Hypersensitivity reactions (including anaphylaxis)
Capillary leak syndrome
Fever and chills
Nausea and vomiting
Elevated transaminases
Asthenia
Rash
Peripheral edema

Drug Interactions

Hepatotoxic drugs may increase the risk of hepatotoxicity
Vaccines: live vaccines may result in severe or fatal infections due to immunosuppression; inactivated vaccines may have decreased efficacy

Curated Content: Needs Vetting Before Put to Clinical Use